3 ms·

GLP-1 isn’t new - the first trials were 20 years ago & there’s a lot of long term data from its use in diabetes management, prior to the weight loss application

• samus 1y ago
  Ok, sure - but are diabetes patients representative of the whole target market for GLP-1? And there will still be an uncomfortable variable that controls the outcome - patient compliance. That's what makes life insurers woozy.
  • oger 1y ago
    I didn't have look on the studies but I would not be surprised if a decent amount of participants were completely healthy individuals. And maybe (more from random sampling) some unsuspicious mildly overweight without other problems. Especially in the earlier cohorts of testing.
    • refulgentis 1y ago
      Right, you should read it though, we're in the weeds over here, it's not just sort of free-assocating chat, we're picking apart specific things about the article. One of them, as I mentioned 4 up, is that the study with the 65% # is confounded because the groupings involve type 1 diabetes, and also, the number rebounds higher than the # who stopped